Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...

Trinity Biotech (TRIB) stock gains on encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...

Trinity Biotech (TRIB) announced results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring ...

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for its ...

But what exactly is driving this sudden attention towards Trinity Biotech, and how does it compare to broader market trends? Let’s explore. Trinity Biotech is a commercial-stage biotechnology company ...

According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion and the Middle East and ...

Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based diagnostic company with a market capitalization of $23.7 million and current trading price of $1.32, is evaluating the potential effects of a recent ...

The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology. Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a ...

The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring t -Metabolomics Diagnostics, a deep-tech machine learning diagnostic ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Trinity Biotech plc acquires, together with its subsidiaries, develops ...

Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes ...